Member Info for Hurst10

Singapore-based biotech Hummingbird Bioscience today announced that San Diego, USA-based Endeavor BioMedicines has acquired exclusive worldwide rights to Hummingbird’s antibody-drug conjugate (ADC), HMBD-501.

French pre-clinical biotech Mablink Biosciences has confirmed earlier rumors that it has agreed to a takeover bid from acquisition-hungry US pharma major Eli Lilly .

This is the 6th deal by Lilly this year.

They are presenting at ESMO

Size buyer at 09.00. Paid the the offer price,watch 131 being lifted in size by early birds in NY, price is no longer important, anything below 200p will be consider a bargain very shortly.

Wise move.

Precision Oncology is major talking point at ESMO, more M&A expected to be announced.Valuations going north.

Early kick off in NY.

Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023

The majors are all presenting and they all want to talk to Avacta, who is not presenting, but no doubt attending by request.

Watch the buyers picking up cheap stock, because of frightened holders.

We will have early size buyers because of this price, keep selling if you have to, we will pick it up and be up 15% before post market prints.

140-5 opening and then Friday buying.

Get on board AM.

Mega size buyers joining us early from NY, this time they will not hide, Convert. Shares already pre sold.

+

ESMO conference with several mayors incl Bayer, Lilly all over precision Oncology just like Novartis( point Biopharma)day long presentation.

Guess what, Avacta attending

Thermo Fisher Scientific doing another transaction.

:We are excited to announce that we have entered into an agreement to acquire

@OlinkProteomics

, a leading provider of next generation proteomics solutions. We look forward to welcoming their team to Thermo Fisher. Learn more in our Press Release: https://bit.ly/3s3Owm2

The sector will have plenty of majors looking for deals in Precision Oncology!

This deal with $50 mill upfront and potential milestone payments up to $2bill shows the appetite for deals among the majors, just days after AACR.

Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases | Monte Rosa Therapeutics

And much more to come next week, post Saturday’s poster presentation.

Novartis attending presentation.

The company have said recently Precision Oncology is where they want to be.

Novartis, Lilly and Roche and Takeda big fans of Fiona.

More to come!

Monday opening price, comfortably in the sixties.

I remember at 114p.

Stick to the day job

With P1b no longer required and when the 2 weekly study shows the expected result, one would expect Dr. Tap and Avacta using the 2 weekly study for P2.

Useful to have est. cost savings which should be significant.

The Poster presentation Saturday should attract an awful lot of interest , with of course Novartis attending.

Watch the size buyers this afternoon writing tickets and pushing the price easily back above 160!

Yes that is how these conferences works, it does put someone like Fiona on the spot for Q&A with Audience.

An RNS in the morning U.K. time, would certainly lift the profile of the company even faster.

Hopefully you all took advantage of the share price two weeks ago.

Another 100/ sales print with plenty of buying going on.

Watch the price back above 160p with nothing left for the buyers.

Fiona’s presentation will be available tomorrow when ?

One could off course also argue, that we have a stock moving higher supported by above average volume and market anticipating the upcoming presentation at AACR conference highlighting AVA3996, AVA6000 and indeed the entire AVA Platform and it‘s potential value going forward.When asked before, industry observers have suggested one applies a 1 billion dollars to each AVA as an average.

The market is growing at pace and we have barely begun.

Good luck to everybody who have taken profit, just don’t forget to jump back on again, we are leaving very soon!

You can see from the size selling prints that there is a buyer around who will pay and most likely will produce buy tickets of size later on.

Believe we will see the following : · The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions

Size buyer moving in , paid up this morning and now will have to pay north of 165 and they will.

The mayors will sit down with Fiona over the next couple of days and deals will be made, before ESMO in Spain.